Urine-based assays for the detection of bladder cancer

被引：32
作者：
Villicana, Patrick [1 ]
Whiting, Bryant [1 ]
Goodison, Steve [2 ]
Rosser, Charles J. [1 ]
机构：
[1] Univ Florida, Coll Med, Dept Urol, Gainesville, FL 32610 USA
[2] Univ Florida, Dept Surg, Jacksonville, FL 32209 USA
来源：
BIOMARKERS IN MEDICINE | 2009年 / 3卷 / 03期
关键词：
bladder cancer; genomics; marker; NMP; 22; proteomics; urinary cytology; urine; IN-SITU HYBRIDIZATION; TRANSITIONAL-CELL CARCINOMA; CARE PROTEOMIC ASSAY; BTA STAT TEST; GENE-EXPRESSION; TUMOR-MARKERS; UROTHELIAL CARCINOMA; PROSTATE-CANCER; HYALURONIC-ACID; FOLLOW-UP;
D O I：
10.2217/BMM.09.23
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Bladder cancer is one of the most prevalent cancers worldwide. Furthermore, nonmuscle invasive bladder cancer has a 70% rate of recurrence, making it a considerable strain to the healthcare system. Patients with bladder cancer require repeat cystoscopic examinations of the bladder to monitor for tumor recurrence. The reason these patients have to undergo these costly, painful, invasive procedures is owing to the absence of accurate urine-based assays to detect the presence of bladder cancer noninvasively. Consequently, the development of a urine-based test to detect bladder cancer would be of tremendous benefit to both patients and healthcare systems. This article reports some of the more prominent urine markers in use today, In addition, the article will highlight some new technologies that are used to investigate novel urinary markers.
引用
收藏
页码：265 / 274
页数：10
相关论文
共 62 条
[1]   Urinary tract infection and patient satisfaction after flexible cystoscopy and urodynamic evaluation [J].
Almallah, YZ ;
Rennie, CD ;
Stone, J ;
Lancashire, AJR .
UROLOGY, 2000, 56 (01) :37-39
[2]   IDENTIFICATION OF A NUCLEAR PROTEIN MATRIX [J].
BEREZNEY, R ;
COFFEY, DS .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1974, 60 (04) :1410-1417
[3]   Bladder cancer stage and outcome by array-based comparative genomic hybridization [J].
Blaveri, E ;
Brewer, JL ;
Roydasgupta, R ;
Fridlyand, J ;
DeVries, S ;
Koppie, T ;
Pejavar, S ;
Mehta, K ;
Carroll, P ;
Simko, JP ;
Waldman, FM .
CLINICAL CANCER RESEARCH, 2005, 11 (19) :7012-7022
[4]   Bladder cancer outcome and subtype classification by gene expression [J].
Blaveri, E ;
Simko, JP ;
Korkola, JE ;
Brewer, JL ;
Baehner, F ;
Mehta, K ;
DeVries, S ;
Koppie, T ;
Pejavar, S ;
Carroll, P ;
Waldman, FM .
CLINICAL CANCER RESEARCH, 2005, 11 (11) :4044-4055
[5]   The health economics of bladder cancer - A comprehensive review of the published literature [J].
Botteman, MF ;
Pashos, CL ;
Redaelli, A ;
Laskin, B ;
Hauser, R .
PHARMACOECONOMICS, 2003, 21 (18) :1315-1330
[6]   Microscopic hematuria [J].
Cohen, RA ;
Brown, RS .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (23) :2330-2338
[7]   Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study [J].
Denzinger, Stefan ;
Burger, Maximilian ;
Walter, Bernhard ;
Knuechel, Ruth ;
Roessler, Wolfgang ;
Wieland, Wolf F. ;
Filbeck, Thomas .
UROLOGY, 2007, 69 (04) :675-679
[8]   Identifying distinct classes of bladder carcinoma using microarrays [J].
Dyrskjot, L ;
Thykjaer, T ;
Kruhoffer, M ;
Jensen, JL ;
Marcussen, N ;
Hamilton-Dutoit, S ;
Wolf, H ;
Orntoft, TF .
NATURE GENETICS, 2003, 33 (01) :90-96
[9]   A molecular signature in superficial bladder carcinoma predicts clinical outcome [J].
Dyrskjot, L ;
Zieger, K ;
Kruhoffer, M ;
Thykjaer, T ;
Jensen, JL ;
Primdahl, H ;
Aziz, N ;
Marcussen, N ;
Moller, K ;
Orntoft, AF .
CLINICAL CANCER RESEARCH, 2005, 11 (11) :4029-4036
[10]   Gene expression in the urinary bladder:: A common carcinoma in situ gene expression signature exists disregarding histopathological classification [J].
Dyrskjot, L ;
Kruhoffer, M ;
Thykjaer, T ;
Marcussen, N ;
Jensen, JL ;
Moller, K ;
Orntoft, TF .
CANCER RESEARCH, 2004, 64 (11) :4040-4048
1234567